Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CPA1 | P15085 | 6/20 | 0.52 |
| ▸ | CPA3 | P15088 | 3/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamide SCHEMBL7277641 | 0.93 | CYP1A2 (0.56) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7330810 | 0.85 | PPARG (0.60) | CYP1A2CPA1PPARGPPARDPPARA | |
| SCHEMBL265063 | 0.84 | CYP1A2 (0.83) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL491524 | 0.84 | CYP1A2 (0.83) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL265514 | 0.84 | CYP1A2 (0.83) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL4886609 | 0.84 | CYP1A2 (0.69) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7333189 | 0.84 | PPARG (0.49) | CYP1A2CPA1PPARGPPARDPPARA | |
| SCHEMBL9577446 | 0.84 | PPARG (0.56) | CYP1A2PPARGPPARDPPARAEPHX2 | |
| SCHEMBL11744397 | 0.83 | CYP1A2 (0.53) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL6722161 | 0.82 | CYP1A2 (0.67) | CYP1A2CPA1CPA3FOLH1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1437401-B1 | Oxidoreductase | IEP GMBH (DE) | 2010-12-15 | — | — | EP | claimed |
| EP-1685248-B1 | OXIDOREDUCTASE FROM METSCHNIKOWIA ZOBELLII | IEP GMBH (DE) | 2010-06-09 | — | — | EP | claimed |
| EP-2123760-A1 | Enzymatic method for enantioselective reduction of keto compounds | IEP GmbH (DE) | 2009-11-25 | — | — | EP | claimed |
| EP-1383899-B1 | ENZYMATIC METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF KETO COMPOUNDS | IEP GMBH (DE) | 2009-09-23 | — | — | EP | claimed |
| EP-1762625-B1 | Reductase gene and use thereof | SUMITOMO CHEMICAL CO (JP) | 2009-07-15 | — | — | EP | claimed |
| US-20080233619-A1 | Process For the Enantioselective Enzymatic Reduction of Keto Compounds | IEP GMBH (DE) | 2008-09-25 | — | — | US | claimed |
| CN-101273136-A | Process for enantioselective enzymatic reduction of keto compounds | IEP GMBH (DE) | 2008-09-24 | — | — | CN | claimed |
| EP-1437401-A1 | Oxidoreductase | Juelich Enzyme Products GmbH (DE) | 2004-07-14 | — | — | EP | claimed |
| EP-1383899-A2 | ENZYMATIC METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF KETO COMPOUNDS | Jülich Enzyme Products GmbH (DE) | 2004-01-28 | — | — | EP | claimed |
| WO-2002086126-A2 | ENZYMATIC METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF KETO COMPOUNDS | JUELICH ENZYME PRODUCTS GMBH (DE) | 2002-10-31 | — | — | WO | claimed |
| US-20250275560-A1 | PROCESS OF MAKING GINGEROL COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | FIRMENICH SA (CH) | 2025-09-04 | — | — | US | disclosed |
| CN-119177259-B | Method for synthesizing optically active (R) -2-hydroxy-4-phenylbutyric acid by utilizing multienzyme catalysis in micro-flow field | 南京工业大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119177259-A | Method for synthesizing optically active (R) -2-hydroxy-4-phenylbutyric acid by utilizing multienzyme catalysis in micro-flow field | 南京工业大学 | 2024-12-24 | — | — | CN | disclosed |
| EP-4307919-A2 | PROCESS OF MAKING GINGEROL COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | Firmenich SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-2403953-B1 | METHOD FOR STEREOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS | CAMBREX IEP GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-4460579-A | HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0080822-A1 | Anti-hypertensive prolinol-based peptides | BEECHAM GROUP PLC (GB) | 1983-06-08 | — | — | EP | disclosed |
| EP-0054862-A1 | Substituted dipeptides, processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase | SCHERING CORPORATION (US) | 1982-06-30 | — | — | EP | disclosed |
| EP-0049506-A1 | N-carboxyalkyl dipeptides, a process for preparing and a pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| EP-0046289-A2 | Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275560-A1 | PROCESS OF MAKING GINGEROL COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | GMPS, UMPS, IMPDH1 | CYP1A2 4282/4885CPA1 4225/4885CPA3 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.